SDI Limited

SDI Limited is a vertically integrated Australian specialist manufacturer of dental consumables. It makes substantially all of its products in Bayswater, Victoria, and exports about 90% of output to more than 100 countries through dealers and distributors. Its portfolio is built around three franchises: (i) aesthetic direct restoratives (composites, glass ionomers, adhesives and cements under the Riva, Luna, Aura, Wave, Zipbond and Stela brands); (ii) tooth whitening (Pola); and (iii) a declining dental amalgam business, which is being replaced by the self-curing composite Stela. The company has grown revenue at about 7.8% a year since FY21 while lifting gross margin to 62.9% (FY25) and 65.6% (HY26). It generates around A$19M of operating cash flow on roughly A$110M of sales. Long controlled by the founding Cheetham family (about 45% ownership), SDI was sold in July 2026 to China's Sinocera, giving the group a Western-market restorative platform alongside its ceramic and zirconia materials businesses.

---

Company's own description (paraphrased from FY25 AR and FY25 Release)

SDI describes itself as a dental technology company that researches, develops, manufactures and markets specialist dental materials. Its principal activities are the manufacture and distribution of dental restorative materials, whitening systems and other dental materials, together with product R&D. The FY25 AR cover frames the business as focused on three areas — tooth whitening, composites and glass ionomers — and cites an addressable market of more than US$4 billion. Operating segments are defined as the manufacture of restorative products, teeth-whitening systems and small dental equipment for sale to dental distributors, dealers and dentists worldwide (FY25 AR Note 4).

Independent characterisation

SDI is a niche, vertically integrated consumables manufacturer with a single-country cost base and a globally dispersed revenue base. Its economic model rests on four features:

1. Manufacturing concentration with export distribution. All manufacturing is in Victoria. Overseas subsidiaries in the US, Germany/UK and Brazil are mainly sales, marketing and warehousing entities, which buy product from the Australian parent at cost plus a mark-up. As a result, the Australian segment books most of the group's manufacturing profit (FY25 Australian segment PBT A$12.0M of a group A$15.1M).

2. A pure product-sale revenue model. All revenue (A$110.4M in FY25) is recognised at a point in time on transfer of goods (FY25 AR Note 5). There is no service, subscription or licensing revenue. A small amount of private-label contract manufacturing exists but was deliberately reduced in FY24 to free capacity for SDI-branded products (FY24 4E).

3. Indirect, dealer-led go-to-market. Customers are dental distributors, dental dealers and, in some markets, dentists directly. No single customer accounts for 10% or more of revenue (FY25 AR Note 4). End users are general dental practitioners, public dental services and government tender programs; government tenders were historically important for amalgam.

4. Mix shift as the core strategic engine. Over a decade SDI has rotated from low-margin amalgam (a silver-mercury alloy facing a global regulatory phase-out) toward higher-margin aesthetics and whitening. This rotation, plus logistics normalisation, automation and price increases, explains most of the 710 basis point gross-margin expansion from FY22 (55.8%) to FY25 (62.9%).

Value-chain position

SDI is an upstream manufacturer. It sources raw materials (resin monomers, glass and filler powders, silver alloy for amalgam, peroxide chemistry for whitening), formulates and packages finished medical devices, registers them with regulators (TGA, FDA, EU MDR notified bodies, ANVISA and others), and sells to intermediaries. It does not own dental clinics or dealer networks. Regulatory registration is a key barrier to entry, and management explicitly regards stringent rules as a competitive moat (FY25 Release; HY26 Report).

Stated strategic priorities (paraphrased from FY25 Release, HY26 Report and FY25 AR)

1. Aesthetics and whitening as the focus of new product development. Stela, originally an amalgam replacement, is being positioned across wider aesthetic categories because of its natural tooth colour and strength.

2. Manufacturing and logistics efficiency. Redevelop the Montrose site and move manufacturing there by December 2027, at an estimated construction and fit-out cost of about A$26M.

3. Automation. Install high-speed production machines; several were commissioned in FY25–HY26 and more were due over the following 6–12 months.

4. Ongoing R&D. Launch one to two products a year while meeting EU MDR deadlines.

5. ESG. An internal working group and an external consultant are building a sustainability risk framework, following an ESG roadmap.

Medium-term targets and guidance

Revenue ambition: AGM presentations (2024 and 2025) refer to Montrose and new products helping to achieve sales of more than A$200M. No target date was given in the materials reviewed.

Profitability ambition: AGM-24 cites a target return (PBT/revenue) of more than 20%, supported by margin improvement. FY25 actual was 13.7%.

Product cadence: one to two new products a year.

Dividend: payout of at least 30% of NPAT (an LTI objective).

Near-term guidance: last formal guidance was the January 2026 trading update (1H FY26 NPAT A$3.5–4.0M). Actual normalised NPAT was A$3.75M and reported NPAT A$3.25M after the doubtful-debt provision. No FY26 full-year guidance was issued.

SDI does not disclose product-level revenue, pricing or launch dates in its filings. The catalog below is based on SDI's published product range and company disclosures. Launch years are given only where disclosed; otherwise they are marked "nd" (not publicly disclosed). Pricing is dealer-set and not disclosed by SDI for any product.

Whitening (FY25: A$32.0M, 29.0% of sales)

Performance notes: whitening fell 4.2% in local currency in FY24 because of strong global competition and weaker discretionary spending. It recovered 2.0% in FY25 on North American and Australian growth. In HY26 it slipped 0.8% because an EU registration issue on one product hit Europe (−8.9%); Australian direct exports grew 17%.

Amalgam (FY25: A$14.4M, 13.0% of sales; HY26: 9.8%)

The category is in structural decline. Amalgam fell 21.9% in FY25 and 23.1% in HY26 in local currency. The EU banned use from 1 January 2025 with exemptions, and the FY25 AR states that EU imports will cease in 2027 and that the UN plans a global phase-out by 2030. North America remains the heaviest exposure (25.8% of North American sales in FY25; 22.1% in HY26). Silver is a commodity input; SDI no longer hedges silver because demand is falling (FY25 AR Note 23).

Equipment (FY25: A$6.2M, 5.6% of sales)

Equipment is described by management as SDI's smallest category and largely complementary. It fell 12.5% in local currency in HY26.

Sources: FY25 AR (FY25 and FY24, plus five-year summary); FY24 4E (FY24 and FY23); FY21, FY22 and FY23 releases (EBITDA, gross margin); S&P/StockAnalysis for FY21–FY23 balance-sheet and cash-flow line items. EBITDA is SDI's own non-IFRS definition, which adds back impairments. EBIT is derived as EBITDA less D&A less impairment.

Income statement

Revenue CAGR: FY21–FY25 four-year CAGR is 7.8%; FY22–FY25 three-year CAGR is 5.1%; FY23–FY25 is effectively flat (+1.2%).

Normalised earnings and source discrepancies.

• FY25 normalised NPAT of A$10.49M excludes the A$1.67M Brazilian capital-loss tax benefit; normalised EPS was 8.83c (FY25 Release).

• FY24 underlying NPAT was A$11.4M excluding impairments (FY24 4E). However, the FY25 Release compares FY25 normalised NPAT against FY24 reported NPAT of A$10.42M, giving "+0.1%". On a like-for-like underlying basis, FY25 normalised NPAT was about 8% below FY24.

• FY23 underlying NPAT was A$7.5M.

• FY23 sales: the FY23 release headline cites A$107.6M while the statutory figure is A$107.855M.

• FY21 "sales revenue and other income" is A$81.67M in the FY25 AR five-year table versus A$81.65M in third-party data.

• Media (Yicai, March 2026) cited FY25 net profit of A$13.1M. This matches FY25 total comprehensive income (A$13.08M), not NPAT (A$12.16M).

HY26 (latest period). Sales A$52.93M (+2.7% in AUD, −1.5% in local currency). Gross margin 65.6% (+210bps). Underlying EBITDA A$8.52M (−1.2%); reported EBITDA A$7.82M (−9.4%) after a A$0.72M doubtful-debt provision. Reported NPAT A$3.25M (−15.2%); normalised NPAT A$3.75M (−2.0%). EPS 2.73c. (Minor discrepancy: HY25 EBITDA is shown as A$8.619M in the commentary and A$8.632M in the Appendix 4D.) Trailing-twelve-month figures to December 2025: sales A$111.8M, reported EBITDA A$20.5M, NPAT A$11.6M, EPS 9.74c (derived).

Commentary on trends, inflections and drivers. The five-year record has three distinct phases.

FY21–FY22: volume up, margin down: The post-COVID rebound produced revenue growth of more than 16% in FY22. Gross margin, however, collapsed by about 570bps to 55.8% because of (a) freight inflation (an extra A$3.3M of freight cost in FY22), (b) a strong rebound in low-margin amalgam tender sales, and (c) adverse regional mix. EBITDA fell 12% despite record sales.

FY23–FY24: the margin inflection: Gross margin rose 530bps in FY24 to 62.1%. The drivers were normalising logistics costs, moving warehousing to the owned Montrose site (which removed third-party logistics costs from September 2023), price increases, automation, and mix toward aesthetics in Europe. EBITDA rose 35.5% to a record A$21.9M on only 3.1% sales growth, showing the high operating leverage of a fixed Australian manufacturing base.

FY25–HY26: margin up, top line stalled: Gross margin kept expanding (62.9% in FY25; 65.6% in HY26) as new high-speed production machines came on line. But group revenue was flat to slightly down: amalgam declined about 22% a year, the Middle East and Asia were volatile, and currency was a headwind. Operating expenses grew 3–4% a year on wage inflation and launch marketing. EBITDA therefore drifted down about 3% in FY25 and about 1% on an underlying basis in HY26. Reported FY25 NPAT growth (+16.7%) is flattered by the one-off tax benefit.

The key analytical point is that SDI had largely exhausted the gross-margin lever. By FY25–HY26 the investment case depended on Stela offsetting amalgam attrition and on the Montrose plant releasing capacity and efficiency from FY28. This "growth gap" is a plausible reason the founding shareholder accepted a 53–58% premium cash exit.

Balance sheet

NTA per share for FY23–FY25 is company-reported and includes right-of-use assets (FY23 51.02c, FY24 50.98c, FY25 58.23c). FY21–FY22 values are tangible book value per share from S&P data (A$0.60 and A$0.64), so the FY22 to FY23 step is partly a definitional break.

HY26 balance sheet (31 December 2025): total assets A$135.8M; cash A$4.6M; borrowings A$15.2M (bank loans A$15.05M plus insurance funding A$0.1M); leases A$1.4M; net debt about A$12.0M; equity A$103.4M; inventories A$29.4M; intangibles A$34.5M. Undrawn facilities were A$10M (working capital) plus A$23M (Montrose construction).

Commentary. SDI moved from net cash of A$9M (FY21) to net debt of A$19.6M (FY23) after debt-funding about A$24M of property, mainly the six-acre Montrose site. It then deleveraged quickly: FY25 net debt fell to A$8.4M, helped by A$4.7M of property sale proceeds and strong operating cash flow. There is no goodwill, as SDI never made a material acquisition. Intangibles are entirely internally capitalised development and IP (A$33.5M in FY25, of which A$9.9M is work-in-progress). Inventory is structurally heavy at about 250 days of COGS because SDI manufactures centrally in Australia and ships to global warehouses.

Cash flow

HY26 cash flow: operating cash flow A$3.04M (HY25 A$7.64M). The drop reflected A$3.7M lower operating receipts net of payments and higher tax paid (A$3.35M). PP&E capex was A$1.53M, intangibles A$2.48M and dividends A$2.26M, so cash fell A$4.4M to A$4.6M.

Commentary. Cash conversion was strong in FY25: operating cash flow of A$19.2M was 158% of NPAT and 90% of EBITDA, helped by an inventory release and normal receivables. FY22 shows the risk on the other side, when a A$4.5M inventory build and A$1.2M receivables growth cut operating cash flow to A$4.3M. FY23 free cash flow was deeply negative because of the Montrose land purchase. Capitalised development has risen from A$1.8M to about A$4.8–5.0M a year, which reflects heavy EU MDR re-registration work on legacy products. That spend is defensive and does not add revenue.

Ratios

Calculation notes. FY21 ROE, ROA and asset turnover use closing balances because FY20 balances were not retrieved. FY21–FY22 interest coverage uses cash interest paid (A$0.06M and A$0.03M); the company was effectively debt-free then. Days ratios use trade receivables, inventory and trade payables against revenue or COGS. All ratios are derived.

Commentary. Returns are adequate but not exceptional (ROIC about 10%). They are held back by the capital-heavy model: about 250 inventory days and roughly A$29M of property, now including undeveloped Montrose land. The cash conversion cycle of about 270 days is long for a consumables company and reflects central manufacturing plus multi-month ocean freight to subsidiary warehouses. Leverage was always conservative: peak net debt/EBITDA was 1.2x in FY23, covenants were complied with, and A$33M of facilities were undrawn at FY25.

Management guidance and consensus

• No public guidance exists beyond HY26. The last explicit guidance was 1H FY26 NPAT of A$3.5–4.0M (January 2026), which was met on a normalised basis.

• There are no consensus forecasts.

FY26 full-year results are not publicly disclosed: as of 16 October 2026. Indicatively, H1 trends point to FY26 sales of about A$110–113M and normalised NPAT of about A$10M before transaction costs. This is an analyst estimate, not company guidance, and the scheme costs of roughly A$1.4M in bonuses plus adviser fees will depress reported FY26 profit.

• As a large proprietary company, SDI will likely lodge financial statements with ASIC, which may become the next public data point.

Bull case (from the perspective of the new owner or a credit counterparty)

1. Margin runway plus Montrose operating leverage. Gross margin is already 65.6%; the new plant targets a 20% pre-tax return on about A$26M of construction spend and releases capacity for the A$200M sales ambition.

2. Stela as an amalgam-replacement winner. It converts a shrinking A$14M amalgam base and enters the larger composite market, where SDI held only about A$58M of aesthetics sales.

3. Sinocera scale and materials science. Access to capital, procurement scale and lab channels (for example DEKEMA) could lift European and Asian distribution and lower cost of goods.

Bear case

1. Growth gap. Group sales were flat for two years (FY24 A$111.2M; FY25 A$110.4M; TTM A$111.8M) as amalgam attrition of more than 20% a year offsets aesthetics growth of about 4%.

2. Execution overload. A plant build and manufacturing relocation by December 2027 coincide with a change of control, board turnover, possible management attrition and post-takeover integration.

3. Channel and macro fragility. Middle East and Brazilian payment issues (HY26 doubtful debt), a whitening business sensitive to discretionary spending, and 90% FX-exposed revenue with no hedging. Chinese ownership could also create friction in some Western tender or regulatory settings.

Key catalysts and monitorables (next 12 months)

• ASIC lodgement of FY26 financial statements (likely by late 2026): watch sales mix, amalgam share (about 10% of HY26) and transaction costs.

• Montrose construction progress (targeted start April 2026; manufacturing transfer by December 2027).

• Management continuity, including Samantha Cheetham's executive role and key R&D personnel.

• Sinocera disclosures (SZSE: 300285) on SDI's contribution, purchase-price allocation and integration plans.

• EU amalgam import cessation (2027, per FY25 AR) and North American amalgam decline.

• Stela registrations and uptake in North America.

• Middle East receivables recovery against the A$0.72M provision.

• US tariff developments affecting Australian-made dental consumables.

Analyst verdict

SDI Limited ended its 41-year listed life as a well-run but sub-scale specialist that had extracted most of the value available from its self-help agenda. Between FY22 and HY26, management delivered a textbook margin turnaround. Gross margin rose by about a thousand basis points to 65.6%, driven by logistics normalisation, warehouse consolidation at Montrose, automation and a steady rotation from amalgam to aesthetics. That pushed EBITDA to around A$21M and operating cash flow to A$19M on a conservative balance sheet. Yet the top line had stalled near A$110M. Amalgam, still 10–13% of sales, is in regulatory free-fall, and aesthetics growth of about 4% a year cannot both offset it and fund the A$26M+ Montrose build while lifting group growth.

The family-controlled register, thin liquidity and absence of analyst coverage left SDI trading at about 9x earnings and about 5.5x EV/EBITDA. That discount made it an obvious target for a strategic buyer with a long horizon. Sinocera's A$1.40 offer — about 8.4x FY25 EBITDA, about 14–16x earnings, and above the independent expert's A$1.21–1.38 range — was a full price for minority shareholders and a sensible succession outcome for a 78-year-old founder. The 98.94% vote reflects that.

Under Chinese ownership, SDI's strategic logic shifts from standalone margin expansion to platform value: Western registrations, the Riva, Pola and Stela brands and a 100-country distribution network become a channel for Sinocera's materials. The key risks are execution and continuity. The Montrose relocation, retention of the Cheetham-era commercial and R&D leadership, and managing geopolitical sensitivity in Western tenders will decide whether the acquisition creates value. For counterparties such as distributors, suppliers and lenders, SDI's credit profile likely improves under a well-capitalised parent. Equity investors can now gain exposure only indirectly, through Sinocera (SZSE: 300285).

---

SOURCES

• SDI Limited, Annual Report 30 June 2025 (ASX, 25 Sep 2025): https://announcements.asx.com.au/asxpdf/20250925/pdf/06pphgvdnvxcz6.pdf

• SDI Limited, FY25 Results ASX and Media Release (28 Aug 2025): https://announcements.asx.com.au/asxpdf/20250828/pdf/06nggwhl21png0.pdf

• SDI Limited, Interim Report and Appendix 4D, 31 Dec 2025 (27 Feb 2026): https://announcements.asx.com.au/asxpdf/20260227/pdf/06wx3wn05d1qkb.pdf

• SDI Limited, Appendix 4E FY24 (27 Aug 2024): https://announcements.asx.com.au/asxpdf/20240827/pdf/06729lcndbn6r7.pdf

• SDI Limited, Trading Update (2 Jul 2024): https://announcements.asx.com.au/asxpdf/20240702/pdf/06555sb4sjqsx7.pdf

• SDI Limited, Interim Report 31 Dec 2024: https://announcements.asx.com.au/asxpdf/20250227/pdf/06g0c5kp360p81.pdf

• SDI Limited, FY23 Results (24 Aug 2023): https://announcements.asx.com.au/asxpdf/20230824/pdf/05szlfdjpkvh5x.pdf

• SDI Limited, FY23 Annual Report: https://announcements.asx.com.au/asxpdf/20230928/pdf/05vf4jd1z78r57.pdf

• SDI Limited, FY22 Results (26 Aug 2022): https://www.asx.com.au/asxpdf/20220826/pdf/45db162zh9s6th.pdf

• SDI Limited, FY22 Annual Report: https://announcements.asx.com.au/asxpdf/20220930/pdf/45fq2rjtfmst2r.pdf

• SDI Limited, FY21 Results (20 Aug 2021): https://www.asx.com.au/asxpdf/20210820/pdf/44zhsc9lj099qx.pdf

• SDI Limited, AGM presentation (28 Nov 2024): https://announcements.asx.com.au/asxpdf/20241128/pdf/06bywz8ppc7l71.pdf

• SDI Limited, AGM presentation (27 Nov 2025): https://announcements.asx.com.au/asxpdf/20251127/pdf/06slkb1v7fv8ff.pdf

• SDI Limited, Chairman's Address AGM (27 Nov 2025): https://bulletin.webull.com/qbd/announcement/20251127/499501964/4f3e389c8741ba764ec022e7ae7f0e91.pdf

• SDI Limited, Trading Update December 2025 (summary): https://investorpa.com/announcement/242602/

• SDI Limited, Scheme Booklet registered with ASIC (18 May 2026): https://announcements.asx.com.au/asxpdf/20260518/pdf/06zq7hxl57khnb.pdf

• SDI Limited, Implementation of Scheme (6 Jul 2026): https://www.listcorp.com/asx/sdi/sdi-limited/news/implementation-of-the-scheme-3374258.html

• InvestSMART, SDI announcements and share-price history: https://www.investsmart.com.au/security/asx/sdi/sdi-limited/announcements

• Kalkine, scheme coverage (conditions, vote, effectiveness): https://kalkine.com.au/news/announcements/sdi-limited-shareholders-vote-9894-in-favour-of-a140-per-share-acquisition-by-sinocera-backed-bidder

• Sharecafe, court approval and effectiveness (24–25 Jun 2026): https://www.sharecafe.com.au/2026/06/24/supreme-court-approves-sdi-limited-scheme-of-arrangement/

• Yicai Global, Sinocera to buy SDI for A$166M (2 Mar 2026): https://www.yicaiglobal.com/news/sdis-stock-pops-as-chinas-sinocera-plans-to-buy-australian-dental-materials-firm-for-usd110-million

• Yicai Global, Sinocera acquires DEKEMA (May 2023): https://yicaiglobal.com/news/2023051906-chinas-sinocera-takes-over-german-dental-gear-maker-dekema-for-usd145-million

• StockAnalysis / S&P Global, SDI balance sheet and cash flow: https://stockanalysis.com/quote/asx/SDI/financials/balance-sheet/

• FNArena, "Dr Boreham's Crucible: SDI" (Mar 2023): https://fnarena.com/index.php/2023/03/16/dr-borehams-crucible-sdi/

• SDI investor presentation to Wilson HTM (Oct 2009): https://data-api.marketindex.com.au/api/v1/announcements/XASX:SDI:XX326151/pdf/inline/presentation-to-wilson-htm-mid-cap-monday-on-19-oct-2009

• Australian Export Awards 2023, International Health winner: https://exportawards.gov.au/en/stories/2023-awards/international-health-winner

• IBISWorld, SDI Limited company profile: https://script.ibisworld.com/australia/company/sdi-limited/9722

• COLTENE, FY2025 results: https://invest.coltene.com/?p=5419

• Shofu, FY Mar-2026 income statement (StockAnalysis): https://stockanalysis.com/quote/tyo/7979/financials/income-statement/

• Dentsply Sirona, FY2025 results: https://dentsplysirona.gcs-web.com/news-releases/news-release-details/dentsply-sirona-reports-fourth-quarter-and-full-year-2025

• iData Research, Global Dental Materials Market 2025–2032: https://idataresearch.com/product/dental-materials-market/

• Meticulous Research, Dental Materials Market to 2036: https://www.meticulousresearch.com/product/dental-materials-market/